Botanix Pharmaceuticals Limited · ASX:BOT
Botanix Pharmaceuticals — Shaw and Partners Medical Cannabis Conference 2017
15 slides from Botanix Pharmaceuticals's conference presentation, May 4, 2017
Slide 1: Botanix presents at Investor Seminar
ASX/Media Release 4 May 2017 For personal use only Botanix presents at Investor Seminar Botanix presents at the Shaw and Partners Investor Seminar Botanix showcased the BTX1503 acne program and initiation of first clinical trial within coming weeks Sydney 4 May March 2017: Medical dermatology co
Slide 2: Media enquiries
Media enquiries Arthur Chan WE Buchan For personal use only P: (02) 9237 2805 E: achan@buchanwe.com.au
Slide 3: Shaw and Partners Medical Cannabis Conference May 2017
For personal use only Shaw and Partners Medical Cannabis Conference May 2017
Slide 4: Investment highlights
+Investment highlights For personal use only Botanix is one of the most compelling emerging companies on the ASX ▪ Multi-billion dollar market with no new products approved in last 20 years Dermatology (for acne) Focused ▪ Faster development pathway for dermatology products, drives lower costs and m
Slide 5: Corporate overview
+Corporate overview For personal use only Innovative medical dermatology company with a clear path to commercialisation Trading information Share price performance Share price (2-May-17) A$0.05 Share price (A$) Volume (m) 52 week low / high A$0.026 / A$0.075 0.08 100 Shares on issue1,2 506.7m Market
Slide 6: Senior leadership: track record of success
+Senior leadership: track record of success For personal use only Proven industry professionals with experience in rapid development of pharmaceuticals Mr Matthew Callahan corporate + IP 20+ FDA approved products Executive Director credited to the broader Botanix leadership team ▪ Developed 3 produc
Slide 7: Botanix's market positioning
+Botanix’s market positioning For personal use only Farming Making products Whole plant or Single chemical extract Health, Cosmetics Regulated pharmaceuticals Veterinary Long development Fast path to market cycle Botanix Pharmaceuticals Ltd. 5
Slide 8: Botanix's acne product – BTX 1503
+Botanix’s acne product – BTX 1503 For personal use only Topically applied gel for the treatment of moderate and severe acne Stops excessive oil or ‘sebum’ production Reduces inflammation Blocks cell proliferation Attacks bacteria BTX 1503 targeting a benign side effect profile Source: Cannabidiol e
Slide 9: Key advantage – synthetic material
+Key advantage 1 – synthetic material For personal use only Use of synthetic cannabidiol greatly increases the chance of clinical success and regulatory approval, at a much lower COGS than naturally extracted material Synthetic cannabidiol Naturally extracted cannabidiol 1 chemical 100+ chemicals Mu
Slide 10: Key advantage – drug delivery
+Key advantage 2 – drug delivery For personal use only PermetrexTM technology drives synthetic cannabidiol directly into the skin – oral administration only delivers ~6% to the blood, most of which does not get to skin organs Unmodified Drug With Permetrex™ Epidermis Dermis Botanix holds the exclusi
Slide 11: Significant and growing market opportunity
+Significant and growing market opportunity For personal use only Global market for acne prescription products market expected to grow to >US$4.5bn and is only a subset of the global dermatology opportunity Value of the global acne prescription market is Top branded acne products containing only gen
Slide 12: Recent dermatology transactions
+Recent dermatology transactions For personal use only Licensing and partnering transactions are potential monetisation options Dermatology transactions US$5,200m Licensing deals Total upfront and US$790m milestone US$770m payments could exceed these US$639m US$445m figures in aggregate US$150m US$9
Slide 13: Strategic and commercialisation focus
+Strategic and commercialisation focus For personal use only Primary strategy is commercialising BTX 1503, with a supportive pipeline of other medical dermatology products and opportunities for near term revenue generation Active pharmaceutical Cannabidiol Botanix product BTX 1503 PermetrexTM BTX 13
Slide 14: Botanix key catalysts
+Botanix key catalysts For personal use only Significant operational milestones expected over the next 9 months, as Botanix launches first human studies and accelerates corporate development Indicative activities and milestones Q2 2017 Q3 2017 Q4 2017 Q1 2018 Phase Ia safety, dosing and pharmacokine
Slide 15: Disclaimer
+Disclaimer For personal use only This presentation prepared by Botanix Pharmaceuticals Limited ("Company") does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction,
Botanix Pharmaceuticals — Shaw and Partners Medical Cannabis Conference 2017 on 6ix